Recent Updates
Recently added Catalysts
ATHE Neutral Sentiment Score: 45/100

Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen

Tuesday, April 29, 2025 4 min read
Key Takeaway: The ASX has received a Change of Director's Interest Notice for Alterity Therapeutics Limited. This notice includes details of three directors: Peter Marks, Lawrence Gozlan, and Brian Meltzer, along with their relevant interests in securities. The report indicates that there have been changes in the number of options held by these directors, but no securities were disposed of or acquired in a significant manner. The information disclosed must be made public as per ASX regulations.

Market Sentiment Analysis

Full Press Release Details

Change of Director's
Change of Director's Interest Notice
Information or documents not available now must
be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information under listing rule
3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Peter Marks
Date of last notice 07 April 2025
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust
made available by the responsible entity of the trust
Note: In the case of a company, interests which
come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest (1) Indirect - Lampam Pty Ltd (2) Direct (3) Indirect - Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>
Nature of indirect interest (including registered holder) (1) Director (2) N/A (3) SMSF
Date of change (1.1) N/A (1.2) N/A (2.1) N/A (2.2) N/A (3.1) N/A (3.2) 24 April 2025
No. of securities held prior to change (1.1) 7,185,968 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 (2.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (3.1) 1,818,182 - FULLY PAID ORDINARY SHARES (3.2) NIL - LISTED OPT EXP 26/02/2027 @ $0.028
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Change of Director's
Class (1.1) FULLY PAID ORDINARY SHARES (1.2) LISTED OPT EXP 31/08/2026 @ $0.01 (2.1) UNLISTED OPT EXP 17/09/2025 @ $0.09 (2.2) UNLISTED OPT EXP 30/12/2027 @ $0.01 (3.1) FULLY PAID ORDINARY SHARES (3.2) LISTED OPT EXP 26/02/2027 @ $0.028
Number acquired (1.1) NIL (1.2) NIL (2.1) NIL (2.2) NIL (3.1) NIL (3.2) 606,061 - LISTED OPT EXP 26/02/2027 @ $0.028
Number disposed (1.1) NIL (1.2) NIL (2.1) NIL (2.2) NIL (3.1) NIL (3.2) NIL
Value/Consideration (1.1) N/A (1.2) N/A (2.1) N/A (2.2) N/A (3.1) N/A (3.2) NIL CONSIDERATION
No. of securities held after change (1.1) 7,185,968 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 (2.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (3.1) 1,818,182 - FULLY PAID ORDINARY SHARES (3.2) 606,061 - LISTED OPT EXP 26/02/2027 @ $0.028
Nature of change (1.1) N/A (1.2) N/A (2.1) N/A (2.2) N/A (3.1) N/A (3.2) Options Issue
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph
(ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Part 3 - +Closed period
Were the interests in the securities or c+ontracts detailed above traded during a closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Change of Director's
Change of Director's Interest Notice
Information or documents not available now must be given to ASX
as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information under listing rule
3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Lawrence Gozlan
Date of last notice 07 April 2025
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made
available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph
(i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest (1) Indirect - Montoya Pty Ltd <Buttercup A/C>
Nature of indirect interest (including registered holder) (1) Director
Date of change (1.1) N/A (1.2) N/A (1.3) N/A (1.4) 24 April 2025
No. of securities held prior to change (1.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.2) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.3) 4,545,455 - FULLY PAID ORDINARY SHARES (1.4) NIL - LISTED OPT EXP 26/02/2027 @ $0.028
Class (1.1) UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.2) UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.3) FULLY PAID ORDINARY SHARES (1.4) LISTED OPT EXP 26/02/2027 @ $0.028
Number acquired (1.1) NIL (1.2) NIL (1.3) NIL (1.4) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 4
Change of Director's
Number disposed (1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL
Value/Consideration (1.1) N/A (1.2) N/A (1.3) N/A (1.4) NIL CONSIDERATION
No. of securities held after change (1.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.2) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.3) 4,545,455 - FULLY PAID ORDINARY SHARES (1.4) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028
Nature of change (1.1) N/A (1.2) N/A (1.3) N/A (1.4) Options Issue
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph
(ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
Part 3 - +Closed period
Were the interests in the securities or c+ontracts detailed above traded during a closed period where prior written clearance was required? No.
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 5
Change of Director's
Change of Director's Interest Notice
Information or documents not available now must be given to ASX
as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information under listing rule
3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Brian Meltzer
Date of last notice 07 April 2025
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made
available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph
(i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest (1) Direct (2) Indirect - BT PORTFOLIO SERVICES
Nature of indirect interest (including registered holder) (1) N/A (2) SMSF
Date of change (1.1) N/A (1.2) N/A (1.3) 24 April 2025 (1.4) N/A (1.5) N/A (2) N/A
No. of securities held prior to change (1.1) 9,415,584 - FULLY PAID ORDINARY SHARES 1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 (1.3) NIL - LISTED OPT EXP 26/02/2027 @ $0.028 (1.4) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.5) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (2) 326,666 - FULLY PAID ORDINARY SHARES
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 6
Change of Director's
Class (1.1) FULLY PAID ORDINARY SHARES (1.2) LISTED OPT EXP 31/08/2026 @ $0.01 (1.3) LISTED OPT EXP 26/02/2027 @ $0.028 (1.4) UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.5) UNLISTED OPT EXP 30/12/2027 @ $0.01 (2) FULLY PAID ORDINARY SHARES
Number acquired (1.1) NIL (1.2) NIL (1.3) 757,576 - LISTED OPT EXP 26/02/2027 @ $0.028 (1.4) NIL (1.5) NIL (2) NIL
Number disposed (1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (1.5) NIL (2) NIL
Value/Consideration (1.1) N/A (1.2) N/A (1.3) NIL CONSIDERATION (1.4) N/A (1.5) N/A (2) N/A
No. of securities held after change (1.1) 9,415,584 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 (1.3) 757,576 - LISTED OPT EXP 26/02/2027 @ $0.028 (1.4) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.5) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (2) 326,666 - FULLY PAID ORDINARY SHARES
Nature of change (1.1) N/A (1.2) N/A (1.3) Options Issue (1.4) N/A (1.5) N/A (2) N/A
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph
(ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 7
Change of Director's
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
Part 3 - +Closed period
Were the interests in the securities or c+ontracts detailed above traded during a closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 8

Frequently Asked Questions

What is the purpose of the Change of Director's Interest Notice?

It informs ASX of changes in a director's interests in securities.

Who is responsible for providing information to ASX?

The entity is responsible as an agent for the director under the Corporations Act.

What kind of information must be reported to ASX?

Changes in direct or indirect interests in securities must be reported.

What happens to information given to ASX?

It becomes ASX's property and may be made public.

Is prior written clearance required during closed periods?

No, the interests mentioned were not traded during a closed period.

Tags: ATHE Viatris Investor Conferences Healthcare Alterity Therapeutics Change of Director ASX Peter Marks
Last updated: Apr 29, 2025